Clinical study on safety of PET probe targeting GLP-1 receptor

Clinical study on safety of PET probe targeting GLP-1 receptor - Clinical study on safety of PET probe targeting GLP-1 receptor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025288

Enrollment

Registered

2017-03-01

Start date

2017-05-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy subjects

Interventions

single dose (1 mCi) 1 day observation single dose (2 mCi) 1 day observation

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Healthy male who have no apparent glucose metabolism disorder. (fasting blood glucose level<100mg/dL and HbA1c<5.5%) 2) Over 20 years old 3) Agreement

Exclusion criteria

Exclusion criteria: 1)BMI<18.5 or 30.0< 2)complication severe renal dysfunction pancreatic tumor pancreatitis 3)past history pancreatitis pancreatic disease 4)unsuitable for and contraindication to Exenatide 5)alcohol intolerance 6)Inadequate patient judged by doctors

Design outcomes

Primary

Measure	Time frame
Evaluation of frequency of adverse event and severity	—

Secondary

Measure	Time frame
Probe accumulation into pancreas	—

Countries

Japan

Contacts

Public ContactHiroyuki Fujimoto

Kyoto University Agency for Health, Safety and Environment

fujimo57@kuhp.kyoto-u.ac.jp075-753-7508

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026